I like this part .

Dr. Terrance Owen, President and CEO, states, "The ability of the new anti-inflammatory formulations to quickly resolve a wide variety of topical infections provides further verification of the effectiveness of the T36(R) technology. Clearly, we are very excited by these results because the new formulations open up therapeutic markets that we had not originally targeted. Even a superficial search of the markets for the treatment of eczema, athlete's foot, toenail infections and insect bites indicates that the market for these new formulations is very large and growing. We now plan on moving forward with the required testing of these products for topical infections as quickly as possible."